Last updated on

Journal of Clinical Oncology
Research Hotspot & Journal Scope - inhibitors


Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.6008
Checkpoint inhibitors assessment in oropharynx cancer (CIAO): Safety and interim results.

Renata Ferrarotto · Diana Bell · M. Laura Rubin · Jiun-Kae Jack Lee · Jason Michael Johnson · Ryan P. Goepfert · Jack Phan · Yasir Elamin · Jeffrey N. Myers · Amy Clark Hessel · Faye M. Johnson · Maura L. Gillison · Andrew G. Sikora · Bonnie S. Glisson · Neil D. Gross ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.4116
Immune checkpoint inhibitors (ICIs) in gastrointestinal (GI) cancer: Immune-related adverse events (IRAEs) and efficacy.

Satya Das · Kristen Keon Ciombor · Sigurdis Haraldsdottir · Yoanna S Pumpalova · Ibrahim Halil Sahin · Yu Shyr · Shih-Kai Chu · Emily Pei-Ying Lin · Chih-Yuan Hsu · Laura W. Goff · Dana Backlund Cardin · Mehmet Asim Bilen · Jordan Berlin · Christina Wu ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.2587
Real-world outcomes of underrepresented patient populations treated with immune checkpoint inhibitors (ICIs): African American descent, poor ECOG performance status, and chronic viral infections.

Neil J. Shah · Matthew Blackburn · Michael R. Cook · Anas Belouali · Michael Serzan · William J Kelly · Athanasios Bikas · Chul Kim · Subha Madhavan · Stephen V. Liu · Michael B. Atkins ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.E16079
Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).

Matthew Labriola · Jason Zhu · Rajan T. Gupta · Shannon McCall · Jennifer Jackson · James R. White · Elizabeth Weingartner · Eric Kong · Peter Simone · Eniko Papp · Kelly Gerding · John K. Simmons · Daniel J. George · Tian Zhang ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.6029
Hyperprogressive disease (HPD) in head and neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint inhibitors (ICI).

Salvatore Alfieri · Roberto Ferrara · Giuseppina Calareso · Stefano Cavalieri · Francesca Platini · Moela Mancinelli · Carlo Resteghini · Ester Orlandi · Nicola Alessandro Iacovelli · L. Ferella · Cesare Piazza · Giulia Apollonio · D. Galbiati · Paolo Bossi · Cristiana Bergamini · Laura D. Locati · Lisa Licitra ·

Medicine
PDF

Highly Related Keywords from inhibitors

Research Hotspot

Journal of Clinical Oncology

Research Hotspot
Journal of Clinical Oncology Related Journals

Popular Journals